1-4 of 4
Anne Marie Nelson
Close
Sort by
Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Alfred L. Garfall, MD, Adam D. Cohen, MD, Simon F Lacey, PhD, Lifeng Tian, PhD, Wei-Ting Hwang, PhD, Dan T. Vogl, MD, Adam Waxman, MD, Eric Lancaster, MD, Anne Marie Nelson, Regina Ferthio, Andrew Fesnak, MD, Anne Lamontagne, Andrea Brennan, Jamie Guilliams, Whitney Lynn Gladney, PhD, J. Joseph Melenhorst, PhD, Regina M Young, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Jennifer Brogdon, PhD, Randi E. Isaacs, MD, Carl H June, MD, Michael C. Milone, Edward A. Stadtmauer, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1863.
https://doi.org/10.1182/blood-2019-131515
Published: 2019
Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1974.
https://doi.org/10.1182/blood-2018-99-119665
Published: 2018
Journal Articles

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Katherine D Cummins, BMBS, Noelle Frey, MD, Anne Marie Nelson, Aliza Schmidt, MS, Selina Luger, MD FRCPC, Randi E. Isaacs, MD, Simon F Lacey, PhD BS, Elizabeth Hexner, MDMS, J. Joseph Melenhorst, PhD, Carl H June, MD, David L Porter, MD, Saar I Gill, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1359.
https://doi.org/10.1182/blood.V130.Suppl_1.1359.1359
Published: 2017
Journal Articles

Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, Alfred L. Garfall, MD, Edward A. Stadtmauer, MD FACP, Simon F Lacey, PhD BS, Eric Lancaster, Dan T. Vogl, MD, Brendan M Weiss, MD, David E Ambrose, BS, Anne Marie Nelson, Fang Chen, PhD, Gabriela Plesa, MD, Irina Kulikovskaya, Vanessa Gonzalez, Minnal Gupta, Regina M Young, PhD, Karen Dengel, BSN, RN, Laura O'keefe, Samantha Le, Celeste Richardson, PhD, Randi E. Isaacs, MD, J. Joseph Melenhorst, PhD, Bruce L Levine, PhD, Carl H June, MD, Michael C. Milone, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 505.
https://doi.org/10.1182/blood.V130.Suppl_1.505.505
Published: 2017